Search Results 751-760 of 16682 for ������������KA���:ZA31���24������ ���������������������������������

  1. A Phase 3, randomized, open-label, controlled study comparing the efficacy and safety of zanidatamab to trastuzumab, each in combination with physician’s choice chemotherapy, for the treatment of participants with metastatic HER2-positive breast cancer - Mayo Clinic

    Jacksonville, Florida: 24-011564; Rochester, Minnesota: 24-011564. NCT ID: NCT06435429. Sponsor Protocol Number: JZP598-303. About this study. The purpose of ...

  2. Head and neck cancers - Doctors and departments - Mayo Clinic

    Learn about innovative treatment for throat cancers, mouth cancers, tongue cancers, tonsil cancers and other cancers that affect the head and neck.

  3. Barriers to Achieving Diabetes Excellence in an American Indian Community in Minnesota - Mayo Clinic

    Rochester, Minnesota: 24-001808. About this study. The purpose of this study is to conduct a survey and focus group of individuals with diabetes and key ...

  4. Atrial tachycardia - Symptoms and causes - Mayo Clinic

    Accessed June 24, 2024. What is an arrhythmia? National Heart, Lung, and Blood Institute. https://www.nhlbi.nih.gov/health/arrhythmias. Accessed July 14 ...

  5. Transcatheter Aortic Valve Replacement for Transcatheter Aortic Valve Failure - Mayo Clinic

    Rochester, Minnesota: 24-013299. About this study. The purpose of this study is to generate clinical evidence on valve safety and performance in subjects ...

  6. Head and neck cancers - Doctors and departments - Mayo Clinic

    Learn about innovative treatment for throat cancers, mouth cancers, tongue cancers, tonsil cancers and other cancers that affect the head and neck.

  7. Head and neck cancers - Doctors and departments - Mayo Clinic

    Learn about innovative treatment for throat cancers, mouth cancers, tongue cancers, tonsil cancers and other cancers that affect the head and neck.

  8. Clinical trials - Oncology (Medical)

    This is a Phase I/II study designed to evaluate if experimental anti-TIGIT/anti-PD-1 bispecific antibody rilvegostomig (AZD2936) is safe, tolerable and ...

  9. A Study to Evaluate KD025 in Subjects with Diffuse Cutaneous Systemic Sclerosis - Mayo Clinic

    The study will be double-blinded for the first 28 weeks followed by an open label extension period of 24 weeks. After un-blinding, the subjects on KD025 ...

  10. Breast cancer - Doctors and departments - Mayo Clinic

    Mayo Clinic has one of the largest and most experienced practices in the United States, with campuses in Arizona, Florida and Minnesota. Staff skilled in dozens ...